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Abstract  
Glucocorticoids are steroid hormones widely used to control many inflammatory 
conditions. These effects are primarily attributed to glucocorticoid receptor 
transrepressional activities but with concomitant receptor transactivation associated 
with considerable side effects. Accordingly, there is an immediate need for selective 
glucocorticoid receptor agonists able to dissociate transactivation from 
transrepression. Triterpenoids have structural similarities with glucocorticoids and 
exhibit anti-inflammatory and apoptotic activities via mechanisms that are not well-
defined. In this study, we examined whether echinocystic acid and its 3-O-glucoside 
derivative act, at least in part, through the regulation of glucocorticoid receptor and 
whether they can constitute selective receptor activators. We showed that echinocystic 
acid and its glucoside induced glucocorticoid receptor nuclear translocation by 75% 
and 55 %. They suppressed the nuclear factor-kappa beta transcriptional activity by 
20% and 70%, respectively, whereas they have no glucocorticoid receptor 
transactivation capability and stimulatory effect on the expression of the 
phosphoenolopyruvate carboxykinase target gene in HeLa cells. Interestingly, their 
suppressive effect is diminished in glucocorticoid receptor low level COS-7 cells, 
verifying the receptor involvement in this process. Induced fit docking calculations 
predicted favorable binding in the ligand binding domain and structural characteristics 
which can be considered consistent with the experimental observations. Further, 
glucocorticoids exert apoptotic activities; we have demonstrated here that the 
echinocystic acids in combination with the synthetic glucocorticoid, dexamethasone, 
induce apoptosis. Taken together, our results indicate that echinocystic acids are 
potent glucocorticoid receptor regulators with selective transrepressional activities 
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(dissociated from transactivation), highlighting the potential of echinocystic acid 
derivatives as more promising treatments for inflammatory conditions.  
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1. Introduction 
 
Glucocorticoids (GCs) are essential steroid hormones for human life. They 
regulate a series of important processes by binding to their cognate receptors, the 
glucocorticoid receptors, (GR) (Evans, 1988). Activated cytoplasmic GR can directly 
bind nuclear DNA and transactivate or transrepress specific genes, critical for growth, 
development, metabolism, immune response and apoptosis. Additionally, it can 
interact with other transcription factors to affect gene expression indirectly (Kassel 
and Herrlich, 2007). The localization of glucococorticoid receptor in mitochondria 
and its implication in the regulation of mitochondrial functions has also been 
documented (Psarra et al., 2005; Sionov et al., 2006; Psarra and Sekeris, 2009a, 2011; 
Psarra et al., 2009b, Du et al., 2009). In addition, binding of GCs to membrane GR 
can also trigger GCs’ non-genomic actions (Borski, 2000). Thus, GCs, through their 
cognate receptor (GR) promote actions, such as induction of gluconeogenesis, 
breakdown of proteins into amino acids, reduction in glucose utilization, and 
stimulation of the mobilization of fatty acids (Rose and Herzig, 2013). More 
importantly, GCs are well known for their anti-inflammatory actions which are 
mediated by a) the negatively glucocorticoid response element mediating DNA-
dependent GR transrepression of inflammatory genes or b) the DNA-independent 
interactions of GR with other transcriptions factors such as NF-κΒ and Stat3 (Refojo 
et al., 2001). Due to their immunosuppressive and anti-inflammatory actions, GCs are 
the most effective therapy in the treatment of acute and chronic inflammatory, as well 
as autoimmune diseases (Baschant et al., 2013; Oakley and Cidlowski, 2013). GCs are 
also considered as a major component of the treatment of many oncology disorders 
due to their proapoptotic properties (Schmidt et al., 2004).  
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However, the supra-physiological doses and chronic use of exogenous GCs 
can give rise to undesirable side effects. Among these are diabetes, osteoporosis, 
muscle wasting, growth retardation in children, disturbed water balance, fat 
redistribution, mood disorders and suppression of the Hypothalamus Pituitary Adrenal 
(HPA) axis resulting in disturbed production and regulation of endogenous cortisol. 
The most predominant side effects of GCs are of catabolic nature. These catabolic 
actions are due to the primarily function of GCs to increase serum glucose by 
inducing gluconeogenesis, which in part relies on protein degradation and lipolysis. 
Although it is assumed that the anti-inflammatory effects of GCs are mainly due to 
GR transrepressional mechanisms, the GR transactivation is accountable for the 
greater part of GCs side effects, such as diabetes and muscle wasting. However, side 
effects such as HPA axis suppression arise from GR transrepressional activities, 
whereas others such as osteoporosis are mediated by both transactivation and 
transrepression (Sundahl et al., 2015). Accordingly, there is a significant need for 
potent selective steroidal or non-steroidal glucocorticoid receptor agonist (SEGRAs) 
or modulators (SEGRMs) as effective as classic GCs, but with a reduced side effect 
profile (Kleiman and Tuckermann, 2007; De Bosscher et al., 2010; Vandevyver et al., 
2013). These compounds can bind to the same or to different GCs binding sites in C-
terminal of the ligand binding domain (LBD) of GR and may cause different GR 
conformational changes (Sundahl et al., 2015). 
  Echinocystic acids (EAs) are triterpenoids that exert anti-inflammatory and 
apoptotic activities. The molecular mechanisms of ECs actions are not yet well-
defined. It is proposed that EAs exert anti-inflammatory actions through interfering 
with NF-κΒ pathway (Joh et al., 2012) and inhibition of proinflammatory cytokine 
expression (Gene et al., 1996; Ryu et al., 2013; Joh et al., 2012, 2014, Ma et al., 
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2016). Apoptotic activities of certain EAs derivatives are attributed to activation of 
JNK- and p38 kinase- mediated mitochondrial pathways and to regulation of protein 
expression of proapoptotic and antiapoptotic molecules (Tong et al., 2004a, 2004b; 
Lee et al., 2005, Cho et al., 2016). Recently, the anti-depression, osteoprotective and 
anti-diabetic activities of EAs have also been proposed (Kumar et al., 2012; Deng et 
al., 2015; Li et al., 2016; Yang et al., 2016). 
In this study, considering the structural and functional similarities of 
echinocystic acid (EA) and its 3-O-glucoside derivative (EA-3G) with GCs (Fig. 1), 
we investigated whether EA and EA-3G mediate their actions, at least in part, through 
the regulation of GR signalling. To this end, three parameters, namely the GR nuclear 
translocation, ligand induced dissociation of GR transactivation and trans-repression, 
and induction of mitochondrial dependent apoptosis in the presence of EAs were 
examined by employing immunohistochemistry, Western blot analysis, luciferase 
reporter gene and chromatin immunoprecipitation (ChIP) assays, in GR positive 
human cervical carcinoma HeLa cell line and/or in GR low level COS-7 cells. Using 
induced-fit docking (IFD) analysis, the predicted binding of EA and EA-3G in the 
LBD was examined and compared to the well-studied dexamethasone (DEX), a 
synthetic glucocorticoid.  
 
2. Materials and Methods 
 
2.1. Chemicals 
 
Dulbecco’s modified Eagle medium (DMEM), fetal bovine serum (FBS), 
MitoTracker Red CMXRos (CMX), and lipofectamin 2000 were obtained from 
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Invitrogen. Molecular weight protein markers were from Fermentas, complete 
protease inhibitors cocktail were purchased from Roche (Mannheim, Germany). All 
other chemicals including dexamethasone (DEX) were purchased from Sigma-Aldrich 
(St. Louis, MO). EAs were purchased from Extrasynthese, France. 
 
2.2. Antibodies 
 
The GR-H300 affinity purified polyclonal GR antibody, which recognizes an 
epitope corresponding to amino acids 121-420 of human GR, and was commercially 
provided by Santa Cruz Biotechnology, was used. Monoclonal antibodies against β-
actin (Sigma Aldrich) and caspase 9 (Cell Signalling), and rabbit polyclonal 
antibodies against phosphoenolpyruvate carboxykinase (PEPCK) (Santa Cruz), 
caspase 3 (Abcam), Bcl-2 (Cell Signalling) and the p65 subunit of NF-κB (Santa 
Cruz) were also applied.  
  
2.3. Cell Culture 
 
Human HeLa and HEK293 cells were maintained in DMEM, supplemented 
with 10% FBS, 2 mM glutamine, and penicillin/streptomycin. Cells were grown at 
37oC in a humidified atmosphere with 5% CO2. 48-72 hrs before treatment, cells were 
cultured in phenol red free-DMEM medium supplemented with 10% charcoal 
inactivated FBS, 2 mM glutamine, and penicillin/streptomycin. 
 
2.4. Immunostaining - fluorescence microscopy 
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Cells grown on coverslips, in DMEM without phenol red supplemented with 
10% charcoal inactivated serum for 48 hrs, were transiently transfected with a 
pEGFPC2GR construct (Psarra and Sekeris, 2011). The next day, cells were incubated 
for 2 hrs with various concentrations of EAs range from 0.1 μM to 20 μM or 0.1μM 
and 1μM  DEX, washed with PBS, fixed for 10 min at -20C in methanol, transferred 
to acetone (-20C) for 2 min, briefly air-dried and mounted in polyvinyl alcohol-based 
anti-fading medium. Additionally, cells grown on coverslips, in DMEM without 
phenol red supplemented with 10% charcoal inactivated serum, were incubated for 
1hr at 37 °C with 200 nM MitoTracker Red CMXRos (CMX), in the presence or 
absence of 10 μM EAs and or 1 μM dexamethasone, washed with PBS, and fixed in 
methanol-acetone (-20C). After three washings (5 min each), immunocytochemistry 
was proceeded using primary GR antibodies (final dilution of 1:50), appropriate 
secondary antibodies conjugated with Alexa fluor 488, provided by Invitrogen, 
diluted 1/500, and 1 μM Hoechst 33342 (Sigma-Aldrich). Specimens were mounted 
in polyvinyl alcohol-based anti-fading medium (Psarra and Sekeris, 2011). Cell 
specimens were observed with a Leica 2000 DM microscope. Images were obtained 
with the optiMOS (Qimaging) camera.  
 
2.5. NF-κB and GR activity 
 
HeLa cells growing on 24-well plates were co-transfected with a NF-κB-
Luciferase (NF-κB-Luc), or an MMTV-GRE (Glucocorticoid response elements of 
the murine mammary tumour virus DNA) promoter-driven luciferase construct (GR-
Luc reporter gene construct) and a β-galactosidase reporter construct, in the presence 
or absence of a pEGFPC2 or a pEGFPC2GR construct (Psarra and Sekeris, 2011) 
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using Lipofectamin 2000 according to manufactures instructions. Cells were treated 
either with TNF α (tumour necrosis factor α; 10 ng/ml) for 6 hrs and/or with 1 μM 
DEX in the presence or absence of 10 μM EAs. Subsequently, cells were lysed in 
report lysis buffer (Promega), following the manufacturer’s protocol, and assayed for 
the expression of luciferase and β-galactosidase activity (Psarra et al., 2009). The light 
emission was measured using a chemiluminometer (LB 9508, Berthold) and adjusted 
to the β - galactosidase activity of the sample. Transfection efficiency was expressed 
as relative luciferase units (RLU). 
 
 
2.6. Electrophoresis and Western Blotting 
  
Cells grown on 6 well plate, for 48 hrs in phenol red free medium 
supplemented with charcoal inactivated fetal bovine serum, were incubated for 
additional 48-72 hrs with 10 μΜ EΑs and/or 1 μΜ DEX and with 10 μΜ EAs or 1 
μΜ DEX in combination with 10 μM RU 486, a synthetic GR antagonist. Cells were 
washed in PBSX1, lysed in buffer A (20 mM Tris pH:7.5, 250 mM NaCl, 0,5 % 
Triton, 3 mM EDTA) supplemented with cocktail preotease inhibitors (Rosche). After 
Bradford protein determination (Bradford, 1976), cell extracts were electrophoresed 
in discontinuous SDS-PAGE and Western blotted with specific antibodies against 
GR, β-actin, PEPCK, Bcl-2, caspase 3 and caspase 9 as previously described (Psarra 
et al., 2005). β-actin expression levels were evaluated for the normalization of the 
PEPCK, GR, Bcl-2, procaspases -3 and -9 expression levels. Enhanced 
chemiluminescence was used for the detection of the protein bands. 
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2.8. ChIP assay 
 
Chromatin immunoprecipitation was performed as previously described 
(Psarra et al., 2011, see also supplementary data). The GR specific monoclonal 
antibody (2F8), produced and kindly provided by Dr. M. Alexis (Hellenic Research 
Foundation), or normal mouse IgG as control were used for the immunoprecipitation. 
The bound DNA fragments were eluted purified, concentrated, amplified and 
quantified by real-time PCR. Binding of GR to the glucocorticoid hormone response 
elements in the promoter region of the PEPCK gene was checked using the following 
primers: Forward: ACAGAGCAGACAATCAATACAGT; Reverse: 
TGAATGCTGGGAGACTTCGA. Recovery of DNA was calculated as percentage of 
input material of the immunoprecipitation.  
 
2.9. Statistical analysis 
 
All results are expressed as mean ± SD (n=3-5). Data were analysed by 
independent t-test or by analysis of variance followed by Tukeys’s post-hoc test using 
SPSS software. Differences were considered significant at a two tailed P value  0.05. 
 
2.10. Induced-fit docking calculations 
 
The ligands (EA, EA-3G, DEX and DAC) were prepared for calculations 
using LigPrep 3.6 (Schrödinger, 2016) with the OPLS3 forcefield (Harder et al., 
2016), while the LBD of GR protein was prepared for docking using its solved 
crystallographic complex (PDB code: 3BQD) with deacylcortivazol (DAC), (Fig. 1). 
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The initial setup of the GR structure for calculations was performed using 
Schrodinger’s “Protein Preparation Wizard” (Schrödinger, 2016). Schrödinger IFD 
calculations (Sherman et al., 2006) of EA, EA-3G, DAC and DEX to the ligand 
binding pocket of GR were then performed (Schrödinger, 2016). Detailed information 
for the analysis and validation of the protocol employed is provided as supplementary 
data. 
 
3. Results 
 
3.1. Echinocystic acid and its 3-O glucoside derivative induce GR nuclear 
translocation. 
 
Structural similarities of EAs with the natural cortisol and the synthetic 
corticosteroid, dexamethasone (Fig 1), prompted us to examine whether EAs are 
capable in inducing GR nuclear translocation. Various concentrations of EAs, range 
from 0.1 μM to 20 μΜ and DEX at concentrations of 0.1 μM and 1 μM was checked 
for their efficacy to induce nuclear translocation of a GFP-GR fused protein 
transiently expressed in HeLa and HEK293 cells. As shown in supplementary Fig. S1, 
DEX at concentration of 0.1 μM and 1 μM activate approximately 100% of nuclear 
localization of the glucocorticoid receptor, as widely demonstrated in the literature. In 
the presence of EA and EA-3G, more than 30% and 10% increase in GR nuclear 
translocation was observed at concentrations of 2 μΜ and 5 μΜ, respectively. EAs at 
concentrations of 10 μΜ, showed further increase in GR nuclear translocation by 5%-
20%, reaching almost a plateau. Since, both compounds were active, at concentration 
of 10 μM, the effect of 10 μM EAs on native GR nuclear translocation in HeLa cells, 
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was checked in comparison to the effect of 1 μM of DEX. As it is shown in Figure 2, 
upon DEX induction, GR is thoroughly translocated from the cytosol to the nucleus, 
as was expected. In the presence of EAs, cytosolic GR staining is reduced, whereas 
GR nuclear staining is strengthen compared to control cells, verifying the steroid 
activity of EAs as regard activation of GR nuclear translocation. Figure 1, also shows 
that EA is more effective (35% increase) than EA-3G (15% increase) in the activation 
of GR nuclear translocation, compared to control cells. This observation indicates that 
both compounds can bind to GR, but possibly EA binding favors GR nuclear 
translocation. 
 
3.2. EAs-induced GR nuclear translocation does not induce GR 
transcriptional transactivation  
 
Luciferase reporter gene assays, using a MMTV-GRE promoter driven 
luciferase construct, revealed that the EAs-induced GR nuclear translocation was not 
accompanied by GR transcriptional activation (Fig. 3). As was expected, incubation 
of HeLa cells with 1 μΜ DEX caused approximately 5 fold increase in GR 
transcriptional activity. On the contrary, in the presence of 10 μΜ EAs, GR 
transcriptional activity was not only increased but slightly reduced compared to 
controls (Fig. 3A).  Assessment of the effect of EAs on the expression of PEPCK, the 
well-known gluconeogenic GR target gene, revealed a moderate reduction in the 
protein levels of PEPCK in HeLa cells, treated with 10 μΜ EAs, for 48-72 hrs (Fig. 
3B). This reduction is more pronounced in the presence of DEX in combination with 
the EAs compounds (Fig. 3B). Similar results were also observed as regards the effect 
of DEX and EAs on GR protein levels.  This observation was also verified in HepG2 
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cells (Data not shown). Normalization of PEPCK protein levels against fluctuations of 
actin and GR protein levels, revealed the expected DEX induced increase in PEPCK 
protein levels (by approximately 100 %), in HeLa cells (Fig. 3C). Combination of EA 
or EA-3G with DEX showed an antagonistic effect of EAs on the DEX-induced 
increase in PEPCK protein levels, resulting in reduction in PEPCK levels by 
approximately 100% (EA) and 60% (EA-3G), (Fig. 3B, 3C). In addition, ChIP 
analysis revealed no statistically significant binding of GR to the promoter region of 
PEPCK, in the presence of EA, whereas EA-3G induced moderate binding, 
approximately 60% lower than that observed by DEX (Fig. 3D). RU 486, the DEX 
antagonist, did not affect the EAs effect on PEPCK expression (Fig 3B, 3C). 
   
3.3. EAs interfere with GR signalling in inhibition of NF-κΒ activity  
 
In order to explore the effect of EAs on NF-κΒ activity, HeLa cells were 
transiently transfected with a NF-κB-Luciferase (NF-κB-Luc) and a β-galactosidase 
construct. Subsequently, cells were triggered with TNF α (10 ng/ml) or equal volume 
of PBS in the presence or absence of EAs (Fig. 4). Measurements of luciferase 
activity revealed that EAs suppressed the transcriptional activity of NF-κΒ in the TNF 
α sensitized cells. This was not evident in the control, non-sensitized cells. More 
specifically, EA caused approximately 25 % inhibition of the TNF α induced NF-κΒ 
transcriptional activation, whereas the EA-3G showed a higher anti-inflammatory 
activity, exhibiting approximately 70 % inhibition of the NF-κΒ activity (Fig. 4A). 
Subsequently, in order to examine whether EAs possible interfere with GR actions, 
the effect of EAs on NF-κΒ transcriptional activity was evaluated in the absence or 
presence of DEX in HeLa cells, transiently overexpressing the GFP or the GFP-GR 
16 
 
fused proteins. As shown in Figure 4B, increased levels of GR caused approximately 
50% reduction in the TNF α-induced NF-κB activity compared to conditions with 
endogenous GR level. As was expected, DEX suppressed the TNF α action on the 
NF-κΒ activity in both controls (GFP overexpressing) and GFP-GR overexpressing 
cells, by approximately 40%. Interestingly, EA-3G showed comparable to DEX 
activity, in both type (GFP and GFPGR overexpressing) of the TΝF α sensitized cells, 
whereas EA exerted weaker inhibitory effect on the NF-κΒ activity, compared to 
DEX (20% inhibition). Both compounds, when administered in combination with 
DEX, showed more than 100% increase in their inhibitory activity compared to 
conditions administered alone. The GR-mediated anti-inflammatory activity of EAs 
was also verified in COS-7 cells; measurements of EAs effect on NF-κB activity, in 
the almost GR-negative COS-7 cells, showed no statistically significant effect of EAs, 
providing strong circumstantial evidence of the involvement of GR in the EAs-
induced NF-κΒ transcriptional inactivation.   
     
3.4. EAs induce mitochondrial impairment and mitochondrial dependent 
apoptosis. 
 
EAs-treated HeLa cells showed a decrease in the incorporation of the 
CMXROS mitochondrial dye when compared to the control DMSO treated cells (Fig. 
5). This dye is exclusively incorporated into functional mitochondria of live cells. 
Therefore, this observation indicates that EAs can induce the depolarization of 
mitochondrial membrane and possibly a mitochondrial dysfunction in HeLa cells. In 
order to explore whether the EAs-induced mitochondrial impairment is also 
associated with induction of apoptosis, evaluation of caspase 3 and caspase 9 protein 
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levels in EAs-treated HeLa cells was attempted by applying Western blot analysis. As 
shown in Figure 6, treatment of HeLa cells with 1 μΜ DEX or 10 μΜ EAs, for 48-72 
hrs, did not cause significant changes in procaspases -3 and -9 protein levels. 
Nevertheless, combined addition of 1 μΜ DEX and 10 μΜ EAs in HeLa cells caused 
proteolytic activation of both caspase 3 and caspase 9, as indicated by the 2-3 fold 
reduction in procaspases protein levels  compared to control cells. This implies that an 
additive effect of EAs and DEX on induction of mitochondrial dependent apoptosis 
may occur. Similar results were obtained as regards the protein levels of the anti-
apoptotic molecule Bcl-2. Incubation of HeLa cells with EAs in combination with 
DEX caused approximately 2 fold reduction in Bcl-2 protein levels compared to 
controls. RU 486, a DEX antagonist, does not have any influence on the effect of EAs 
on the expression of apoptosis related GR target genes (Fig. 6). 
 
3.5. Induced-fit docking results. 
 
Induced-fit docking of DEX, DAC, EA and EA-3G to GR was performed 
using the solved GR LBD bound to DAC as starting model. This crystal structure 
when solved revealed that the size of the ligand binding pocket is expanded to a size 
of 1070 Å3, approximately double than the GR-DEX binding pocket (540 Å3), and is 
better suited for the docking of bulkier ligands such as EA-3G studied here (Suino-
Powell et al., 2008).  The hypothesis was that EA-3G with its 3-O-glucoside can form 
an intricate network of interactions with the receptor in the upper-part of the ligand 
binding pocket while leaving the structure of the coactivator binding site intact, 
similar to that observed for the high affinity DAC ligand through its phenylpyrazole 
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group (Suino-Powell et al., 2008). The IFD scoring results are shown in Table 1, with 
the EAs predicted to bind well in the LBD but less strongly than DEX and DAC.  
The predicted binding interactions of EA and EA-3G are shown in Fig. 7.  EA 
occupies close to the same space as DEX and its rings A-D are co-planar. The C3 -
OH group mimics interactions of the DEX C-3 headgroup ketone through hydrogen 
bonds with Gln570 (H3) and Arg611 (H5). Additionally, the C3 hydroxyl forms a 
hydrogen bond with Phe623 backbone O (β-strand) between H5 and H6. There are no 
further hydrogen bonding interactions with H3. The C16 hydroxyl is not involved in 
hydrogen bonding interactions and is pointed towards H7 with shifting away of its 
Gln642 sidechain compared to the DEX bound structure; the C17 carboxylate is 
directed towards H11 exploiting a favourable interaction with Cys736 sidechain -SH. 
The mainly hydrophobic nature of EA means that the ligand exploits many favourable 
interactions with non-polar residues from different helices (Fig. 7Β). For EA-3G, the 
3-O-glucoside moiety protrudes into the upper part of the binding cavity in a similar 
manner as was observed for DAC but towards H3 rather than H5. The three 
glucopyranose hydroxyls are engaged in a number of hydrogen bonding interactions: 
two parallel hydrogen bonds with Arg611 (H5) sidechain NH’s and additional 
hydrogen bonds with Pro541 O from the loop preceding H1. With the important 
Gln570 residue, a hydrogen bond contact is strained (non-ideal angles) and its H3 
sidechain is pushed away, the potential significance of which is discussed later. The 
network of interactions formed by the glucopyranose moiety leads to an adjustment in 
the orientation of the ligand core compared to EA so that it is no longer co-planar with 
DEX. While the ligand core scaffold retains numerous favourable interactions with 
non-polar residues, the C17 carboxylate group now occupies the position of the C16 
hydroxyl for EA binding and further pushes the Gln642 (H7) sidechain parallel to the 
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helix rather than the perpendicular orientation observed in the GR-DEX LBD 
complex (also discussed further below). The C16 hydroxyl is directed towards 
Asn564 but does not hydrogen bond in the predicted model. 
 
Table 1: Induced-fit docking calculation resultsa  
Ligand GlideScore IFDscore 
DAC -17.44 -556.40 
DEX -15.89 -552.09 
EA-3G -13.20 -549.69 
EA -11.28 -540.38 
a Scores for top-ranked poses based on the IFDscores. 
 
4. Discussion  
 
Glucocorticoids, regulate intermediate metabolism, growth, development, 
stress, immune response, and apoptosis via their cognate receptors, via genomic and 
non-genomic mechanisms of actions (Barnes, 1998; Sapolsky et al., 2000). Genomic 
actions of GCs, results in positive or negative regulation of the expression of a 
plethora of genes, through direct binding of GR to positive or negative glucocorticoid 
responsive elements (GREs) or through physical interactions of GRs with other 
transcription factors. Cortisol is the most abundant endogenous glucocorticoid in 
human subjects, produced under the control of HPA axis (Evans, 1988). Among the 
cortisol-positively regulated target genes are genes encoding lipoprotein receptors and 
enzymes of glucose, lipid, amino acid metabolism and anti-inflammatory protein, 
while negatively regulated genes are genes encoding CRH, proopiomelanocortin, 
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adiponectin, and pro-inflammatory cytokines (Dostert and Heinzel, 2004; Degawa-
Yamauchi et al., 2005, Rose and Herzig, 2013). Besides, by physical interaction of 
GR with other transcription factors, such as NF-κΒ, cortisol negatively regulates the 
expression of many inflammatory cytokines, which constitute NF-κΒ target genes 
(Liberman et al., 2007; Psarra and Sekeris, 2008). Thus, cortisol affects human 
metabolism as well as human immune responses (Bamberger et al., 1996; Dostert and 
Heinzel, 2004; Degawa-Yamauchi et al., 2005; Wang, 2005; Rose and Herzig, 2013; 
Oppong and Cato, 2015). Due to the anti-inflammatory actions of cortisol, GCs as 
well as synthetic glucococorticoids, are widely used in medicine to treat inflammatory 
diseases and autoimmune disorders (Buttgereit et al., 2015). Despite the favorable 
anti-inflammatory actions of GCs, the chronic use of them, as therapeutic drugs, give 
rise to many side effects. In addition, patients receiving long term glucocorticoid 
therapy, frequently have tissue-specific glucocorticoid resistance (Yang and Ray, 
2013). Thus there is a high need for the discovery of glucocorticoid activators with 
reduced side effects.  
Certain echinocystic acids exert anti-inflammatory, anti-apoptotic, anti-
depression, osteoprotective and anti-diabetic activities (Kumar et al., 2012; Deng et 
al., 2015; Li et al., 2016; Yang et al., 2016). The molecular mechanisms of these 
actions are not clearly defined. It is proposed that the anti-inflammatory action of EAs 
is mediated through NF-κB inactivation. Thus, echinocystic acid is shown to suppress 
the lipopolysaccharide- and the IL-1β- induced iNOS, and to inhibit pro-inflammatory 
cytokines expression, IL-6, IL-1β and TNF-α, via inhibition of IKKβ phosphorylation 
and/or NF-κB inactivation in several type of cells, particularly in macrophages (Ryu 
et al., 2013; Hyam et al., 2013; Joh et al., 2014, Ma et al., 2016). In addition, 
echinocystic acid is shown to inhibit the TPA-induced myeloperoxidase activity, (Joh 
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et al., 2014) and to down-regulate the expression of nitric oxide synthase, 
cyclooxygenase-2, and that of the inflammatory mediators, nitric oxide and 
prostaglandin E2, (Gene et al., 1996; Joh et al., 2012, Ma et al., 2016).  
Likewise GCs are known to exert anti-inflammatory activity, through 
suppression of NF-κΒ activity, pro-inflammatory cytokines and cyclooxygenase 
expression and through inhibition of prostaglandin synthesis at the level of 
phospholipase A2 as well as at the level of cyclooxygenase/PGE isomerase (COX-1 
and COX-2) (Goppelt – Struebe et al., 1989; Baschant et al., 2013;).  
Since GCs and EAs share common anti-inflammatory activities, our aim has 
been to identify whether EAs are able to mediate their actions, at least in part, through 
activation of GR trans-repressional activities and ideally with preferentially little or 
no effect on trans-activating GR activities. Our results clearly show that echinocystic 
acid and its 3-O glucoside are able to induce 75% and 55%, nuclear translocation of 
GR, indicating that the structural similarities of EAs with GCs enable them to bind to 
cytosolic GR and to trigger its nuclear translocation and activation.  
EAs-induced nuclear translocation of GR does not end up in its transcriptional 
activation, as indicated by the assessment of EAs-induced activation of the GRE-
driven luciferase gene expression. Consistent with this observation was the finding 
that the PEPCK expression, that constitute a well-known GR target gene, and a key 
regulatory enzyme of gluconeogenesis, remained unaffected in response to EAs 
treatment. The inability of EAs to induce PEPCK gene expression might be attributed 
to the EAs-induced GR conformational changes that do not favor (in the case of EA) 
or restrict (by 60 % compared to DEX, in the case of EA-3G) GR binding to the 
promoter region of the PEPCK gene, as indicated by ChIP analysis. Interestingly, EAs 
could act as DEX antagonists as indicated by the EA- and EA-3G- induced reduction 
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(by 100% and 60%, respectively) in the DEX-induced increase in PEPCK protein 
level and the EAs-induced moderate reduction in the DEX-induced GR transcriptional 
activation. RU 486, which is a DEX antagonist, did not alter the EAs effect on 
glucocorticoid receptor target gene expression. The relative limited induction of 
protein expression of PEPCK by DEX, compared to controls, could be attributed to 
the observed DEX-induced decrease in GR protein levels. This effect, which is also 
observed by others (Shimojo et al., 1995; Cidlowski and Cidlowski, 1981) may be 
assigned to the NCoR1 complex-mediated ligand-induced repression of the 
glucocorticoid receptor gene (Ramamoorthy and Cidlowski, 2013).  
Although unable to induce transcription of the GRE-regulated genes, EAs-
induced nuclear translocation of GR was accompanied with suppression of the TNF-α 
-induced NF-κB activation in ΗeLa GR-positive cells.  The EAs inhibitory effect on 
NF-κΒ transcriptional activation was shown in both the non- and the TNF α- 
sensitized HeLa cells. This effect appears to be exerted at the transcriptional level, 
since there were no changes observed in the levels of the p65 subunit of NF-κB in 
EAs-treated HeLa cells compared to controls. Interestingly, 10 μΜ EA-3G are as 
effective as 1 μM DEX in the reduction of the NF-κΒ transcriptional activity, 
exhibiting more than 40% inhibition, whereas, 10 μM οf the echinocystic acid 
induced weaker (20%), compared to DEX, suppression of the NF-κΒ activity. 
Moreover, the EAs suppressive action on the TNF α-induced NF-κΒ activity is 
approximately doubled in the presence of DEX, in HeLa cells either expressing 
endogenous GR levels or transiently overexpressing the glucocorticoid receptor, in 
comparison to control cells. The inhibitory effect of EAs on the NF-κΒ activity is 
abolished in GR low level COS-7 cells, further supporting the involvement of GR in 
this process. Although EA is more effective in the induction of the GR nuclear 
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translocation, the glucoside moiety of the EA-3G molecule might cause 
conformational changes that favor the GR-mediated NF-κB transcriptional 
inactivation, by affecting binding and requirement of other components of the multi-
protein dynamic repression complex, as has been described for other dissociated 
molecules (Dezitter et al 2014, Sundahl et al 2015). Moreover, EAs compounds could 
differentially affect GR posttranscriptional modification, such as phosphorylation, 
crucial for fine regulation of GR activities. We also cannot exclude that EAs could 
possible act in an additional GR-independent manner.   
The induced-fit docking calculations revealed a number of predictions 
consistent with the experimental observations. Both EA and EA-3G are predicted to 
bind in the LBD forming a number of key receptor-ligand interactions. Maintaining 
the location of helix H3 (and H4) has been cited (Liu et al., 2016) as more critical for 
GR nuclear translocation than the location of H12 on the basis that RU 486 can also 
trigger GR nuclear migration (Lewis-Tuffin et al., 2007); alternatively, it is generally 
accepted that the location of H12 is critical to the release of the GR complex from its 
HSP chaperone (Liu et al., 2016; Bledsoe et al., 2002). Neither of the top-ranked IFD 
poses for EA or EA-3G are predicted to hydrogen bond with Asn564 (H3), an 
important contact observed for steroid agonists and proposed as favourable for 
nuclear translocation by holding H3 in its canonical position. EA-3G has also 
predicted contacts that are strained with Gln570 (H3). Taken together, these binding 
features could be a source of the weaker EA-3G translocation (55%) compared to its 
aglycone EA analogue (75%) and when compared to DEX (100%). Equally, the 
pushing away of Gln642 in H7 by the C17 carboxylate of EA-3G could be a 
contributing factor to its observed promising (transrepressional) activity (EA-3G ≈ 
DEX > EA) through possible stabilization effects on the H12 position, in a manner 
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previously reported for the highly potent synthetic glucocorticoid, mometasone 
furoate (He et al., 2014). The predicted binding affinities of EA-3G and EA are 
similar but less than for DEX. This lends support to the antagonistic effect of these 
ligands on DEX activity which is consistent with the lower PEPCK levels observed 
for DEX in the presence of the EAs. The proposed hypotheses while consistent with 
the experimental observations are based on docking models. The key factor in 
glucocorticoid physiology is what ligand dependent structural reorganizations of the 
GR LBD allow a receptor to function as a more potent activator. High ligand binding 
affinity for the receptor is a determining factor in potency but cellular co-factors also 
play important roles through recognition of the surface conformational changes 
caused by binding of different ligands (He et al., 2014). Subtle induced changes can 
have profound effects on cofactor selectivity.   
In addition to their anti-inflammatory actions, GCs are well known for their 
cell type specific effect on induction of apoptosis (Gruver-Yates and Cidlowski, 2013) 
that give rise to their use as anticancer agents, in the treatment of specific type of 
cancers (Pufall, 2015). The molecular mechanisms of the GCs-mediated induction of 
apoptosis involve down regulation or inhibition of anti-apoptotic molecules, such as 
Bcl-2, as well as upregulation or activation of pro-apoptotic molecules such as BAX-2 
(Lotem and Sachs, 1995; Salomons et al., 1997; Rieger et al., 1999; Murphy et al., 
2000; Das et al., 2004; Almawi et al., 2004; Hoijman et al., 2004; Mahmoud et al., 
2009; Lopez-Royuela et al., 2010; Melarangi et al., 2012; Zaman et al., 2014). The 
mitochondrial dependent induction of apoptosis by DEX has been observed in several 
types of cells. In accordance with the GC-driven induction of apoptosis, HeLa cells 
treated with EAs showed alterations in mitochondrial membrane potential, as 
indicated by the reduced accumulation of the CMX dye. These alternations resulted in 
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mitochondrial dependent apoptosis, as proved by the two to three reduced level of 
procaspase -9, -3 and Bcl-2 when EAs are used in combination with DEX. These 
observations are in accordance with the EAs induction of apoptosis in hematopoietic, 
HepG2 cells and human ovarian cancer cells at concentrations higher than 20 μΜ 
(Tong et al., 2004a, 2004b; Lee et al., 2005, Kim et al., 2015, Cho et al., 2016). The 
additive effect of 10 μΜ EAs and 1 μM DEX on the NF-κΒ transcriptional 
inactivation and the induction of apoptosis at concentration lower than that reported in 
the literature may have an important role in immunosuppressive and anticancer 
combinations therapy, which aims at minimizing side effects of any single drug.  
In conclusion, EAs showed anti-inflammatory and apoptotic activities that are 
predicted to be mediated by binding of EAs to GR and triggering its nuclear 
translocation. EAs-induced GR nuclear localization interferes with GR signalling, 
resulting in dissociation of GR transactivation from transrepression as indicated by 
the activation of GR transrepressional activities on NF-κB activity and the negative 
effect of EAs on the expression of GR target genes, involved in glucose metabolism 
and in the GCs-induced apoptosis (Fig. 8). Since EAs could favor GR tranrepression 
over transactivation, they could be considered as selective glucocorticoid receptor 
activators, at least as regards reduction of the side effect of gluconeogenesis. Further 
analysis is required to delineate their mechanisms of actions and to explore, their 
potential for therapeutic use as anti-inflammatory and anticancer drug, with reduced 
side effects, alone or in combination with DEX, in vivo models.  
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Figures Legends 
Figure 1. 
Chemical structures of synthetic glucocorticoids DEX and DAC (GR agonists), the 
synthetic antiglucocorticoid RU 486 (GR antagonist), together with EA and its 3-O-
glucoside analogue EA-3G studied in this work.  
 
Figure 2. 
EA and its 3-O glucoside induced GR nuclear translocation in HeLa cells.  HeLa 
cells cultured in hormone depleted medium for 48 hrs were incubated with 10 μM 
EAs (diluted in DMSO) or 1 μM DEX (diluted in EtOH). Control cells were treated 
with DMSO and EtOH at the same dilution as treated cells.  Following 2 hrs 
incubation cells were washed in PBS and fixed in methanol-acetone. For 
immunochemistry analysis antibodies against GR (GR-H300) and anti-rabbit 
secondary antibodies Alexa Fluor® 488 conjugated (Green) were applied. Hoechst 
33342 (Blue) dye for nuclear staining was also used. Bars indicate 30 μΜ. Relative 
GR nuclear localization is expressed as percentage of mean intensity of GR nuclear 
staining per mean intensity of total GR cellular staining. Data are expressed as mean ± 
S.D. (n> 30), ***P<0.001, compared to controls. 
 
Figure 3. 
EAs do not induce GR transcriptional activation in HeLa cells. A. HeLa cells 
cultured in hormone depleted medium were transiently co-transfected with a GR-Luc 
reporter gene construct and a β-galactosidase reporter construct. Cells were further 
incubated for 48 hrs and subsequently treated with 10 μΜ EAs and/or 1μM DEX, for 
6 hrs. Control cells were treated with DMSO (1:1000) and EtOH (1:1000). Cells were 
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lysed and activity of luciferase and β-galactosidase was measured in cell extracts. 
Luciferase activity was normalized against β-galactosidase activity and expressed as 
relative luciferase unit. Data are expressed as mean ± S.D. (n=3), **P<0.01; 
***P<0.001. B. Western blot analysis of PEPCK, GR, and β-actin protein levels was 
performed in extracts from HeLa cells treated with the indicated amounts of EAs, 
DEX, and or RU 486, in hormone depleted medium, for 48 hrs. Commercially 
provided antibodies were used. C. Normalization of PEPCK protein levels against β-
actin and GR protein levels. D. Assessment of GR binding to the GRE of the 
promoter region of PEPCK gene in HeLa cells treated with 1 μM DEX or 10 μM EAs 
for 2 hrs. ChIP analysis was performed using the monoclonal 2F8 a-GR antibody. 
Immunoprecipitated DNA encompassing GRE of the promoter region of PEPCK gene 
was assessed by real-time PCR. Recovery of DNA was calculated as percentage of 
input material of the immunoprecipitation. Relative recovery was expressed as GR 
recovery of each sample compared to control.  The results of three triplicate 
measurements of two independent experiments as means ± SD are shown. * P< 0.05; 
**P<0.01; ***P<0.001. 
    
Figure 4 
EAs suppress NF-κB transcriptional activity in HeLa cells possibly through 
regulations of GR signalling. A. HeLa cells cultured in hormone depleted medium 
were transiently co-transfected with a NF-κΒ Luc reporter gene construct and a β-
galactosidase reporter construct. Cells were further incubated for 48 hrs and 
subsequently treated with 10 μΜ EAs or DMSO (Control) and/or 10 nM TNF α, for 6 
hrs. Cells were lysed and activity of luciferase and β-galactosidase was measured in 
cell extracts. Luciferase activity was normalized against β-galactosidase activity and 
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expressed as relative luciferase units. Effect of EAs on NF-κB activity was also 
evaluated in HeLa GFP or GFP-GR overexpressing cells, in the presence or absence 
of DEX (Β) or in low level GR expressing COS-7 cells (C).  Data are expressed as 
mean ± S.D. (n=3-5) and analyzed by analysis of variance followed by Tukeys’s post-
hoc test (*P<0.05; **P<0.01; ***P<0.001). D. Western blot analysis of the p65 
subunit οf NF-κΒ in HeLa EAs and/or DEX treated cells. β-actin protein levels was 
examined for the normalization of the results. Commercially provided antibodies 
against p65 and β - actin were used.   
 
Figure 5. 
EAs induce mitochondrial dependent apoptosis. 
Fluorescence microscopy analysis of the CMXROS and Hoechst dye in EAs-treated 
HeLa cells revealed occasionally reduced incorporation of the CMXROS dye in 
mitochondria of EAs-treated cells compared to control cells (white arrows).  Bars 
indicate 30 μΜ.  
 
Figure 6. 
EAs in combination with DEX result in induction of apoptosis 
A. Western blot analysis of β-actin, Bcl2, pro-caspase 3 and pro-caspase 9 protein 
levels in cell extracts from HeLa cells treated with 10 μM EAs and/or 1 μM DEX, for 
6 hrs in hormone depleted medium, was performed using commercially provided 
antibodies. B. Mean intensity of Bcl-2, pro-caspase-3 and procaspase 9 protein levels 
normalized against β-actin protein levels. (Means ± SD, n=3, ***P<0.001 compared 
to relative controls).  
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Figure 7.  
Binding of (A) DEX (PDB code: 1M2Z) and (B) DAC (PDB code: 3BQD) to the GR 
LBD from their respective crystal structures, together with the predicted binding of 
(C) EA and (D) EA-3G from induced-fit docking calculations.  
 
Figure 8 
EAs as potent dissociated compounds for GR transrepression and 
transactivation.  
A novel mechanism of EAs actions includes binding of EAs to GR and induction of 
its translocation from the cytoplasm to the nucleus. EAs – GR complex leads to 
dissociation of GR transrepression from transactivation. EAs favor activation of GR 
tranrepressional activities contributing to EAs anti-inflammatory actions (red box), 
whereas antagonistic or no effect of EAs on GCs-induced GR transactivation, leads to 
reduce GCs side effects (green box), at least as regards induction of the expression of 
the gluconeogenic enzyme PEPCK. In addition, EAs interfering with GCs signalling 
promotes mitochondrial dependent apoptosis.  
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